Tylenol Aims High with Brand Re-launch
from Euromonitor Podcasts Hosted by Euromonitor International
Tylenol sales have fallen drastically from 2007 to 2012 due to product recalls and production shutdowns. Now, Johnson and Johnson, which owns the brand, is promoting a re-launch of Tylenol with a new advertising campaign focusing on what pain relief enables, rather than the hindrance of pain. Chris Schmidt, Consumer Health Industry Analyst at Euromonitor, states that although sales of Tylenol in the US fell by almost one billion US dollars since 2007, the brand image hardly suffered at all and Tylenol should be able to climb back to the top three analgesic brands by 2017. Lots of brands claim to be number one… but can they prove it? At Euromonitor International, we help brands build trust through evidence-based research. Our claim validation service ensures your marketing messages are backed by real data. Stand out in a crowded market. Visit euromonitor.com/claims to learn more.
Embed this episode
What this episode covers
Tylenol sales have fallen drastically from 2007 to 2012 due to product recalls and production shutdowns. Now, Johnson and Johnson, which owns the brand, is promoting a re-launch of Tylenol with a new advertising campaign focusing on what pain relief enables, rather than the hindrance of pain. Chris Schmidt, Consumer Health Industry Analyst at Euromonitor, states that although sales of Tylenol in the US fell by almost one billion US dollars since 2007, the brand image hardly suffered at all an...
No transcript yet.